1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997
2. A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer;O’Reilly;Proc Am Soc Clin Oncol,2004
3. Gemcitabine versus GEMOX (gemcitabine + oxaliplatin) in nonresectable pancreatic adenocarcinoma: Interim results of the GERCOR/GISCAD Intergroup phase III;Louvet;Proc Am Soc Clin Oncol,2003
4. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma;Heinemann;Proc Am Soc Clin Oncol,2003
5. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297;Berlin;J Clin Oncol,2002